[ad_1]
Maria Halasz, CEO of Cellmid Limited (ASX: CDY), tells Proactive Investors the key achievements since the $ 10 million raise last September, and details the next phases of growth.
Cellmid is a life science company whose consumer sector has consistently generated double-digit revenue growth and is moving towards profitability. He is also the owner and developer of the largest intellectual property portfolio around midkine; a target drug indicated in cancer, inflammatory diseases and fibrosis.
Source link
